Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 RT Inhibitor
Tenofovir diphosphate triethylamine is an inhibitor of HIV-1 reverse transcriptase, exhibiting a Ki value of 1.55 μM for DNA and 0.022 μM for RNA. This antiretroviral compound is a valuable tool in the study of HIV replication and resistance, facilitating research into the mechanisms of AIDS pathology and treatment strategies. Its potent inhibitory activity supports the development of therapeutic approaches aimed at curbing HIV infection. -
HIV-1 Inhibitor
AzddMeC is a potent, selective nucleoside analogue that functions as an inhibitor of HIV-1 reverse transcriptase, effectively blocking HIV-1 replication. The compound demonstrates strong antiviral activity, with EC50 values of 9 nM in HIV-1-infected human peripheral blood mononuclear cells and 6 nM in HIV-1-infected human macrophages. In addition to its antiviral properties, AzddMeC serves as a versatile click chemistry reagent, containing an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) with alkyne- and DBCO- or BCN-containing molecules, respectively, making it a valuable tool in chemical biology research. -
HIV Inhibitor
Pentosan Polysulfate is an orally bioavailable sulfonated polysaccharide that acts as an HIV inhibitor by interfering with viral attachment to host cells. Its potent and selective anti-HIV activity positions it as a valuable compound for HIV research. Additionally, Pentosan Polysulfate possesses anti-inflammatory and pro-chondrogenic properties, making it relevant for studies related to interstitial cystitis. -
HIV-1 RT Inhibitor
Tenofovir diphosphate is a potent inhibitor of HIV-1 reverse transcriptase, with a Ki of 1.55 μM for DNA and 0.022 μM for RNA. This active metabolite of tenofovir demonstrates significant antiretroviral activity, making it a valuable tool for studying HIV replication and pathogenesis. Tenofovir diphosphate is utilized in research focused on AIDS and the development of effective therapies targeting HIV-1. -
HIV Replication Inhibitor
Triptonine B is a sesquiterpene pyridine alkaloid that functions as an HIV replication inhibitor. It demonstrates potent antiviral activity in H9 lymphocytes, with an EC50 value of less than 0.10 μg/mL. This compound is applicable in research focusing on HIV biology and the development of therapeutic strategies against HIV infection. -
HIV-1 Entry Inhibitor
BMS-818251 is a highly potent small-molecule inhibitor that targets HIV-1 entry, exhibiting an EC50 value of 0.019 nM. Its superior efficacy is demonstrated by over 10-fold increased potency compared to related compounds across a diverse panel of 208 HIV-1 strains. BMS-818251 enhances its inhibitory effects by interacting with conserved gp120 residues, specifically the β20-β21 hairpin, making it a valuable tool for research in HIV resistance and therapeutics. -
HIV-1 RT Inhibitor
HIV-1 inhibitor-69 is a potent inhibitor of HIV-1 reverse transcriptase (RT), a critical enzyme in the viral replication process. This compound effectively disrupts the reverse transcription of viral RNA into DNA, thereby inhibiting viral propagation. It is primarily utilized in research focused on HIV-1 pathogenesis and the development of antiretroviral therapies. -
HIV Inhibitor
12-Bromododecanoic acid is a bromo fatty acid that acts as an inhibitor of HIV replication. It has demonstrated efficacy in reducing HIV replication in CEM-SS T cells with an EC50 of 38 µM. This compound can also be utilized in the synthesis of clickable derivatives of myristic acid, highlighting its versatility in chemical research related to viral inhibition and fatty acid modification. -
HIV Inhibitor
HIV-1 Inhibitor-10 is a potent nanomolar inhibitor targeting the maturation process of HIV-1. This compound disrupts viral assembly, thereby preventing viral replication. It serves as an important research tool for studies focused on HIV biology and the development of novel therapeutic strategies against HIV-1 infections. -
Non-nucleotide HIV Reverse Transcriptase Inhibitor
Ainuovirine is a second-generation non-nucleoside HIV reverse transcriptase inhibitor (NNRTI) that targets HIV reverse transcriptase. By non-competitively binding to the enzyme, Ainuovirine effectively disrupts the reverse transcription of viral RNA, thereby inhibiting HIV replication. This compound is utilized in research focused on human immunodeficiency virus (HIV) type 1 infection. -
HIV-1 Integrase Inhibitor
GSK3739936 is a potent allosteric inhibitor of HIV-1 integrase, exhibiting an IC50 value of 11.1 nM and an EC50 of 1.7 nM. In addition to its inhibitory effects, GSK3739936 demonstrates weak inhibition of cytochrome P450 enzymes (IC50 > 24.3 μM). This compound also showcases favorable pharmacokinetic properties in preclinical models, characterized by rapid absorption, low to moderate clearance rates, and excellent oral bioavailability, making it a promising candidate for further research in HIV therapeutics. -
HIV-1 Inhibitor
NBD-14189 is a potent HIV-1 entry antagonist that demonstrates an IC50 of 89 nM against the HIV-1 HXB2 pseudovirus. This compound targets the HIV-1 gp120 protein, effectively inhibiting viral entry and showcasing notable antiviral activity with an EC50 of less than 200 nM. NBD-14189 is suitable for research applications focusing on HIV-1 entry mechanisms and antiviral drug development. -
HIV-1 Inhibitor
HIV-1 inhibitor-33 is a highly selective inhibitor targeting HIV-1 with an EC50 value of 8.6 nM, demonstrating significant potency against viral replication. With a CC50 of 18 μM in MT-4 cells, this compound presents a favorable safety profile for research. It is suitable for studies focused on AIDS research and the development of antiviral therapies. -
HIV-1 Protease Inhibitor
DPC 684 is a highly selective HIV-1 protease inhibitor that demonstrates potent inhibitory activity with an IC90 ranging from 5.7 to 40 nM and a Ki value of 0.021 nM. By competitively inhibiting HIV-1 protease, it effectively blocks the cleavage of viral polyproteins, thereby disrupting viral replication. DPC 684 exhibits low protein binding and offers broad-spectrum inhibition against various wild-type and mutant strains of HIV-1, making it a valuable tool for research in HIV biology and therapeutic development. -
HIV-1 Inhibitor
GSK3532795 hydrochloride is a potent, orally bioavailable second-generation inhibitor targeting HIV-1 maturation. It demonstrates strong antiviral activity with EC50 values of 1.9 nM against HIV-1 wild type, 10.2 nM in human serum, and 2.7 nM and 13 nM for the HIV-1 V370A and ΔV370 variants, respectively. This compound is valuable for research applications focused on the pathogenesis and treatment of HIV-1 infections. -
HIV-1 Inhibitor
HIV-1 inhibitor-51 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets the reverse transcriptase enzyme of HIV-1, demonstrating potent antiviral activity against both wild-type and mutant strains. It exhibits a high binding affinity with a KD of 2.50 μM and shows significant inhibitory potency with an IC50 of 0.03 μM against wild-type HIV-1 reverse transcriptase. Additionally, HIV-1 inhibitor-51 has effective EC50 values ranging from 2.22 to 53.3 nM against a range of clinically relevant mutant strains, making it a valuable tool for research in HIV-1 drug resistance and antiviral drug development. -
HIV Inhibitor
Neotripterifordin is an inhibitor of HIV replication, demonstrating significant antiviral activity. This compound exhibits an EC50 of 25 nM in H9 lymphocyte cells, indicating its potency against HIV. Neotripterifordin is valuable for research applications focused on understanding HIV pathogenesis and developing potential therapeutic strategies. -
HIV-1 Integrase Inhibitor
S 1360 is a potent and selective inhibitor of HIV-1 integrase, effectively disrupting its catalytic activity with an IC50 of 20 nM. This compound exhibits antiviral activity against both X4 and R5 tropic strains of HIV-1, including variants resistant to NRTIs, NNRTIs, and PIs. In MTT assays using HIV-1 IIIB-infected MT-4 cells, S 1360 shows an EC50 of 200 nM and a CC50 of 12 μM, making it a valuable reagent for research in HIV-1 treatment and resistance mechanisms. -
Anti-HIV Agent
KNI-102 is a potent anti-HIV agent that primarily targets HIV protease, exhibiting an IC50 value of 100 nM. This compound demonstrates significant antiviral activity, making it a valuable tool for research into HIV replication and pathogenesis. Its efficacy in inhibiting protease activity supports its application in developing novel therapeutic strategies for HIV infection. -
HIV Inhibitor
Droxinavir hydrochloride is an antiviral compound that acts as an HIV protease inhibitor. This compound significantly impedes viral replication by inhibiting the enzymatic activity essential for HIV maturation. Droxinavir hydrochloride is primarily utilized in research related to HIV infection and the development of antiviral therapies. Its role in protease inhibition makes it a valuable tool in studying HIV life cycle and resistance mechanisms. -
HIV-1 IN Chain Transfer Inhibitor
L-870810 is a potent inhibitor of HIV-1 integrase (IN) chain transfer, effectively interfering with the integration of viral DNA into the host genome. This compound exhibits significant antiviral activity, making it a valuable tool for researchers studying HIV-1 replication and potential therapeutic strategies. Its mechanism of action positions it as a key reagent for investigations into HIV-1 pathogenesis and drug development. -
HIV-1 Entry Inhibitor
RPR103611 is a derivative of betulinic acid that functions as a potent HIV-1 entry inhibitor. It displays IC50 values of 80 nM for CCR5-tropic virus YU2, 0.27 nM for CXCR4-tropic virus NL4-3, and 0.17 nM for dual tropic virus 89.6. This compound is valuable for research focused on the mechanisms of HIV-1 entry and the development of antiviral therapies. -
HIV-1 Inhibitor
HIV-1 Inhibitor-16 is a potent inhibitor targeting HIV-1 with an EC50 value of 1.3 nM against wild-type strains. This compound also demonstrates significant activity against various resistant strains, including HIV-1 K103N, E138K, Y181C, and L100I, with EC50 values of 5.4 nM, 9.2 nM, 22 nM, and 35 nM, respectively. Its favorable solubility profile and stability in liver microsomes make it a valuable tool for research, while its minimal interaction with CYP enzymes reduces concerns regarding toxicity. This compound is ideally suited for studies focused on HIV-1 resistance and treatment strategies. -
HIV-1 Inhibitor
HIV-1 inhibitor-71 is a targeted inhibitor of HIV-1 that interferes with the transport of endocytosed HIV-1 particles into nuclear envelope invaginations (NEIs). This action effectively disrupts the viral entry process, thereby inhibiting productive infection. This compound is valuable for research applications focused on HIV-1 infection mechanisms and the development of novel antiviral strategies. -
HIV-1 RNase H Inhibitor
HIV-1 integrase inhibitor 9 is a potent inhibitor of HIV-1 RNase H, exhibiting an IC50 of 12.3 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for research into HIV-1 replication and potential therapeutic strategies. Its role in inhibiting viral enzyme function supports the investigation of novel antiviral agents targeting HIV-1. -
HIV REV/RRE Binding Inhibitor
Fleephilone is a fungal metabolite derived from Trichoderma harzianum that acts as an HIV REV/RRE binding inhibitor. It effectively disrupts the interaction between the REV protein and RRE RNA, exhibiting an IC50 value of 7.6 μM. This compound is valuable for research focused on HIV replication mechanisms and the development of antiviral strategies targeting RNA-protein interactions. -
HIV Inhibitor
HIV-1 inhibitor-36 is a potent inhibitor targeting HIV-1, exhibiting significant antiviral activity against the virus. It has potential applications in the development of novel latency-reversing agents, making it a valuable tool for research in HIV treatment and eradication strategies. This compound may facilitate the understanding of viral latency and aid in the advancement of therapeutic approaches to HIV infection. -
HIV-1 Reverse Transcriptase Inhibitor
HI-236 is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase, effectively disrupting the replication of the HIV virus. It demonstrates exceptional antiviral activity, with an IC50 value of less than 0.001 μM against wild-type HTLVIIIB. This compound is primarily utilized in HIV research, particularly in the development of antiretroviral therapies. -
HIV Inhibitor
F1839-I is an HIV inhibitor derived from the fungus Stachybotrys. It exhibits anti-HIV activity with an IC50 value of 15.6 μM, demonstrating its potential in therapeutic applications against HIV infection. Additionally, F1839-I has shown weak cytotoxicity, supporting its feasibility for further research in antiviral drug development. -
HIV-1 Nef Binder, Calnexin Binder
NSC 13987 is a selective inhibitor of the HIV-1 Nef protein, specifically targeting site I. By binding to Nef, NSC 13987 disrupts its interaction with calnexin, leading to the restoration of cholesterol efflux that is typically inhibited by Nef. This compound is valuable for research into HIV-associated atherosclerosis, providing insights into the mechanisms behind HIV infection and its impact on lipid metabolism. -
HIV-1 Inhibitor
VIRIP, derived from human α1-AT(353-372), functions as an inhibitor of HIV-1 by targeting the gp41 fusion peptide. It prevents the entry of HIV-1 into host cells, thereby disrupting the viral lifecycle. This reagent is applicable in virology research and studies focused on HIV-1 entry mechanisms. -
HIV-1 Inhibitor
Kadsuracoccinic acid A is a tetracyclic natural compound targeting HIV-1. It exhibits significant anti-HIV-1 activity in vitro, with an EC50 value of 68.7 μM. This compound is valuable for research in the development of antiviral therapies and understanding HIV-1 inhibition mechanisms. -
HIV Inhibitor
HIV-1 inhibitor-70 is a bifunctional inhibitor targeting both wild-type and K103N mutant reverse transcriptases of HIV-1. This compound effectively disrupts the replication of the virus, making it valuable in HIV research and therapeutic investigations. Its dual inhibitory action provides insights into resistance mechanisms and aids in the development of effective treatments for HIV infections. -
HIV protease inhibitor
SB 204144 is a potent inhibitor of HIV protease, disrupting the proteolytic processing of viral polyproteins and hindering the maturation of infectious HIV particles. This compound is valuable for research on HIV pathogenesis and immune system diseases, enabling studies on antiviral effects and the development of new therapeutic strategies against HIV. Its application in virology underlines its relevance in understanding and combating HIV infection. -
HIV Inhibitor
B07 is a potent HIV inhibitor that targets viral replication mechanisms. In addition to its antiviral properties, B07 also exhibits spermicidal activity with an EC50 of 1.5 mg/mL. This compound has valuable applications in HIV research and the development of contraceptive agents. -
HIV-1 Inhibitor
GS-9822 is a potent HIV-1 inhibitor that specifically targets the LEDGF/p75-integrase interaction, demonstrating robust antiviral activity with an IC50 of 0.07 μM against wild-type HIV-1 viruses. It exhibits high in vitro metabolic stability and favorable oral pharmacokinetic properties, characterized by low systemic clearance across various preclinical animal models, including rats, dogs, and monkeys. GS-9822 is a valuable tool for research applications focused on understanding HIV-1 integration and developing therapeutic strategies against viral infections. -
HIV-1 Inhibitor
Fosamprenavir-d4 is a deuterium-labeled inhibitor targeting HIV-1 protease. As a prodrug of Amprenavir, Fosamprenavir is hydrolyzed by cell phosphatases, converting it into Amprenavir, which subsequently binds to the active site of HIV-1 protease. This binding prevents the processing of essential viral precursors, inhibiting the production of mature and infectious virions. Fosamprenavir-d4 is useful for research focused on HIV-1 infection and therapeutic strategies against the virus. -
HIV Inhibitor
Tsugafolin is a dehydroflavone that acts as an inhibitor of HIV. It exhibits weak anti-HIV activity with an IC50 value of 118 μM while demonstrating low cytotoxicity at concentrations below 150 μM. Isolated from the plant Vitex leptobotrys, Tsugafolin serves as a valuable tool for research applications focused on HIV-1 replication and the development of therapeutic strategies. -
HIV
(S)-BMS-378806 is a potent HIV-1 inhibitor that primarily targets the gp120-CD4 interaction, disrupting the crucial binding necessary for viral entry into host cells. This compound demonstrates micromolar inhibition of HIV-1 gp120-CD4 binding, making it a valuable tool for understanding HIV pathogenesis and developing therapeutic strategies. The design of (S)-BMS-378806 was informed by detailed studies of protein-ligand interactions, leading to the synthesis of innovative symmetrical N,N'-disubstituted aminoureas and thioureas. Its inhibitory activity has been confirmed through HIV-1 gp120-CD4 capture ELISA. -
HIV-l Encoded Protease Inhibitor
L-738872 is a potent orally active inhibitor of the HIV-1 encoded protease. It effectively inhibits viral replication by interfering with the processing of viral polyproteins, which is critical for the maturation of infectious HIV particles. This compound is valuable in research focused on understanding HIV protease functionality and developing antiretroviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
Urushiol (15:3) is an inhibitor of HIV-1 reverse transcriptase, demonstrating moderate inhibitory activity with an IC50 value of 55.36 μM. This compound, derived from the leaves of Rhus verniciflua, exhibits significant cytotoxicity against prostate cancer PC-3 cells and normal MRC-5 cells. Urushiol (15:3) is relevant for research into anti-HIV-1 therapies and the study of prostate cancer biology. -
HIV NNRT Inhibitor
BI-2540 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor targeting HIV. This compound exhibits significant antiviral activity by inhibiting the reverse transcription process, thereby preventing viral replication. BI-2540 is utilized in research for the development of therapeutic strategies against HIV and contributes to the understanding of HIV resistance mechanisms. -
HIV-1 RT Inhibitor
L 738372 is a non-competitive reversible inhibitor of HIV-1 reverse transcriptase (RT) with a reported inhibition constant (Ki) of 140 nM against dTTP. This compound demonstrates synergistic inhibition of RT activity when used in combination with nucleoside analogs such as azidothymidine triphosphate, didexoyinosine triphosphate, or didexoycytidine triphosphate. Notably, L 738372 exhibits enhanced inhibitory potency against azidothymidine-resistant RT variants (D67N, K70R, T215Y, K219Q), making it a valuable tool for advancing research in HIV treatment strategies. -
HIV Inhibitor
H-Gly-Pro-Gly-NH2 is a tripeptide that serves as an inhibitor of HIV-1 and HIV-2 replication. Demonstrating EC50 values of 35 µM for HIV-1 IIIB and 30 µM for HIV-2 ROD, H-Gly-Pro-Gly-NH2 reduces viral replication by disrupting capsid formation in vitro. This compound possesses significant antiviral activity, making it a valuable tool for research into HIV and related viral mechanisms. -
HIV
GPI2A is a 20-mer antisense oligonucleotide targeting the HIV-1 gag gene. This compound demonstrates significant inhibition of the viral proteins p55 and its cleavage products p39/41, making it a valuable tool for HIV research. GPI2A may be used to study the mechanisms of HIV replication and the potential for therapeutic intervention in HIV-1 infections. -
HIV-1 Inhibitor
GSK3532795 oxalate is a potent second-generation inhibitor of HIV-1 maturation, acting primarily through the disruption of viral particle assembly. It exhibits notable efficacy with EC50 values of 1.9 nM for HIV-1 wild type, 10.2 nM in human serum, as well as 2.7 nM and 13 nM for the HIV-1 V370A and ΔV370 variants, respectively. This compound is essential for research focused on HIV-1 infection mechanisms and therapeutic strategies. -
HIV-1 Inhibitor
HIV-1 inhibitor-34 is a potent and selective inhibitor of HIV-1, exhibiting an EC50 value of 6.4 nM in HIV-1 assays and a CC50 of 16 μM in MT-4 cells. This compound is valuable for research applications focused on understanding HIV-1 replication and pathogenesis, making it a useful tool for studies related to AIDS therapeutics. -
HIV Inhibitor
SJ-3366 is a potent inhibitor of HIV non-nucleoside reverse transcriptase. This compound demonstrates significant inhibitory activity at sub-nanomolar concentrations, functioning through a typical non-nucleoside mechanism. SJ-3366 is utilized in research applications focused on HIV replication and the development of antiretroviral therapies. -
Fungicidal Agent
N,N-Bis(3-aminopropyl)dodecylamine serves as a potent fungicidal agent targeting Aspergillus niger. It exerts its antifungal activity by inducing oxidative stress and modulating the activity of various antioxidant and mitochondrial enzymes in a concentration- and time-dependent manner. Additionally, this compound disrupts fungal organelles and alters mitochondrial morphology, leading to impaired mitochondrial functions. N,N-Bis(3-aminopropyl)dodecylamine is valuable for research into fungicidal mechanisms and the role of oxidative stress in Aspergillus niger. -
Active Compound
Phenylpyruvic acid is a precursor to phenyllactic acid and serves as an active compound with antifungal properties. This reagent enhances the antifungal activity of various lactic acid bacterial strains when incorporated into defined growth media. Phenylpyruvic acid exhibits significant inhibitory effects against fungal contaminants such as Aspergillus niger and Penicillium roqueforti. Additionally, it influences the enzymatic activity of the pentose phosphate pathway in rat brain homogenates, notably reducing glucose-6-phosphate dehydrogenase activity. This compound is valuable for research applications in microbiology and metabolic studies.
